An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma

Conclusion.TKM‐080301 was generally well tolerated. In this early‐phase study, antitumor effect for TKM 080301 was limited. Further evaluation as a single agent in large randomized trials is not warranted.

Source: The Oncologist - June 17, 2019 Category: Cancer & Oncology Authors: Imane El Dika, Ho Yeong Lim, Wei Peng Yong, Chia-Chi Lin, Jung-Hwan Yoon, Manuel Modiano, Bradley Freilich, Hye Jin Choi, Tsu-Yi Chao, Robin K. Kelley, Joanne Brown, Jennifer Knox, Baek-Yeol Ryoo, Thomas Yau, Ghassan K. Abou-Alfa Tags: Hepatobiliary, Chinese Edition, Clinical Trial Results Source Type: research